Psychotic DisordersPsychoses, Substance-InducedSubstance PSchizophreniaAffective Disorders, PsychoticProdromal SymptomsSchizophrenic PsychologyEarly Medical InterventionDelusionsSubstance-Related DisordersParanoid DisordersPsychiatric Status Rating ScalesAntipsychotic AgentsHallucinationsSchizotypal Personality DisorderSchizophrenia, ParanoidBipolar DisorderDelirium, Dementia, Amnestic, Cognitive DisordersMarijuana AbuseReceptors, Neurokinin-1Substance Abuse Treatment CentersDiagnosis, Dual (Psychiatry)Social AdjustmentMental DisordersNeuropsychological TestsCognition DisordersEarly DiagnosisCommunity Mental Health ServicesBrief Psychiatric Rating ScaleRisk FactorsAge of OnsetDiagnostic and Statistical Manual of Mental DisordersSchizophrenia, ChildhoodThiobarbituric Acid Reactive SubstancesLongitudinal StudiesCognitive TherapyParental DeathMental Health ServicesHumic SubstancesCatatoniaHazardous SubstancesRisperidoneBrainStreet DrugsHospitals, PsychiatricComorbidityMagnetic Resonance ImagingTime FactorsMarijuana SmokingTachykininsHaloperidolFollow-Up StudiesCannabisCase-Control StudiesNeurokinin-1 Receptor AntagonistsPsychomotor AgitationAnalysis of VarianceAlcoholismInterview, PsychologicalMood DisordersThinkingPsychometricsTranquilizing AgentsProjective TechniquesCommunity Mental Health CentersSchizophrenic LanguageSelf MutilationNeurokinin AHallucinogensIncestSeverity of Illness IndexSubstance Abuse DetectionPsychotropic DrugsDibenzothiazepinesFamily TherapyModels, PsychologicalDepressive DisorderFamilyTreatment OutcomeCommitment of Mentally IllMethamphetamineRorschach TestClozapineN,N-DimethyltryptamineDangerous BehaviorSchizophrenia, DisorganizedIntelligenceSocial EnvironmentDesigner DrugsDisease ProgressionPrevalenceUnited StatesDyskinesiasLithium CarbonateStatistics as TopicDermatoglyphicsAmphetamine-Related DisordersPerformance-Enhancing SubstancesHospitalizationQuestionnaires